GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Intrinsic Value: Projected FCF

FluoroPharma Medical (FluoroPharma Medical) Intrinsic Value: Projected FCF : $0.00 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-27), FluoroPharma Medical's Intrinsic Value: Projected FCF is $0.00. The stock price of FluoroPharma Medical is $0.0001. Therefore, FluoroPharma Medical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for FluoroPharma Medical's Intrinsic Value: Projected FCF or its related term are showing as below:

FPMI's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.28
* Ranked among companies with meaningful Price-to-Projected-FCF only.

FluoroPharma Medical Intrinsic Value: Projected FCF Historical Data

The historical data trend for FluoroPharma Medical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Intrinsic Value: Projected FCF Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.68 -0.93 -1.11 -1.14

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.11 -1.14 -1.14 -0.50 -1.14

Competitive Comparison of FluoroPharma Medical's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, FluoroPharma Medical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Price-to-Projected-FCF falls into.



FluoroPharma Medical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get FluoroPharma Medical's Free Cash Flow(6 year avg) = $-2.64.

FluoroPharma Medical's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec16)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-2.63808+-10.179/0.8)/34.027
=-1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FluoroPharma Medical  (OTCPK:FPMI) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

FluoroPharma Medical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/-1.1120345354655
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FluoroPharma Medical Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus